Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Myriad Genetics Inc(MYGN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for MYGN
11/13/2026: MYGN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Myriad Genetics is a specialized molecular diagnostics company focused on hereditary cancer, women's health, and pharmacogenomics. Its primary strength lies in its strong clinical evidence base and established physician referral networks for products like MyRisk and GeneSight. The company's main growth story centers on scaling its mental health diagnostics platform, though it faces stiff competition in the maturing genetic testing market. Key risks include price pressure from payers, execution challenges in growth segments, and an inconsistent history of profitability. Myriad currently suits growth-oriented investors interested in precision medicine, provided they can monitor the company's ability to maintain margins and navigate a competitive landscape.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers exposure to the precision medicine sector but faces significant competitive and execution challenges. |
| Momentum investor | Mixed fit | Momentum investment is conditional on positive clinical data and growth acceleration signals. |
| Value investor | Weak fit | The stock valuation is primarily driven by future growth potential rather than current cash flow yield. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses capital on growth. |
| Low-risk investor | Weak fit | The diagnostics industry and Myriad's specific risk profile involve high volatility and regulatory exposure. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Genetic testing stocks are highly sensitive to clinical trial outcomes and changes in reimbursement policy. |
| Valuation risk | Medium / high | Growth expectations are often priced into the stock, leaving little room for error in execution. |
| Competition risk (diagnostics/molecular) | High | The market is becoming increasingly commoditized with aggressive pricing from large players. |
| Business quality | Medium | While the company has strong clinical assets, historical execution has been inconsistent. |
| Dividend income | Low / none | Investors should not expect income generation from this holding. |
| Execution risk | Medium / high | Scaling new tests like GeneSight requires significant commercial effort and payer education. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 544.84M USD | Price to earnings Ratio - | 1Y Target Price 5.44 |
Price to earnings Ratio - | 1Y Target Price 5.44 | ||
Volume (30-day avg) 2.7M shares | Beta 1.61 | 52 Weeks Range 2.74 - 8.09 | Updated Date 11/13/2026 |
52 Weeks Range 2.74 - 8.09 | Updated Date 11/13/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.35 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Diagnostics & Research
- BUY participation
- 68.8%
- Active BUY / eligible
- 11 / 16
- 30-Day BUY Count Change
- 0
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior
Flat / Range-Bound
The stock price has been trading within a narrow range with minimal directional movement.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 12.99% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 11/13/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Oncology Testing | MyRisk hereditary cancer test, tumor molecular profiling. | This is the core foundation of the company's revenue, serving patients and oncologists. |
| Mental Health (Pharmacogenomics) | GeneSight test for psychiatric medication guidance. | A key growth segment targeting the large and underserved mental health diagnostics market. |
| Women's Health | Prenatal screening (Prequel) and carrier screening (Foresight). | Provides stable testing volumes in the reproductive and prenatal medicine category. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 54.05 | Enterprise Value 647.14M | Price to Sales(TTM) 0.68 |
Enterprise Value 647.14M | Price to Sales(TTM) 0.68 | ||
Enterprise Value to Revenue 0.81 | Enterprise Value to EBITDA -23.47 | Shares Outstanding 95.92M | Shares Floating 79.56M |
Shares Outstanding 95.92M | Shares Floating 79.56M | ||
Percent Insiders 4 | Percent Institutions 94.74 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.